Acute Hypercalcaemia Protocol

Hydrate · Block · Eliminate · v1.1
How to use this tool: Enter the calcium and albumin, renal function, ECG findings, symptoms and the suspected cause. The tool returns a stepwise emergency protocol covering hydration, anti-resorptive therapy and the indications for dialysis.
1. Calcium & Albumin
2. Clinical Status
3. Suspected Aetiology
The Two Causes That Cover 90%

Primary hyperparathyroidism and malignancy account for approximately 90% of all hypercalcaemia. The clinical distinction is critical because management differs fundamentally. PTH level is the key discriminator: PTH elevated or inappropriately normal = primary hyperparathyroidism; PTH suppressed (low) = malignancy or other non-PTH cause. Always send PTH, PTHrP, 25-OH vitamin D, and 1,25-dihydroxyvitamin D together.

FeaturePrimary HyperparathyroidismMalignancy-Associated
OnsetChronic, indolentAcute, rapid rise
Calcium levelUsually mild (10.5-12 mg/dL)Often severe (> 14 mg/dL)
PTHElevated or inappropriately normalSuppressed (low)
PTHrPNormalElevated (humoral hypercalcaemia of malignancy)
ChlorideElevated (> 103) due to bicarbonaturiaNormal
Definitive treatmentParathyroidectomyTreat underlying malignancy
The Physiology of Dehydration in Hypercalcaemia

Hypercalcaemia causes a vicious cycle of dehydration: (1) Calcium impairs renal concentrating ability (nephrogenic diabetes insipidus), causing polyuria. (2) Hypercalcaemia causes nausea and vomiting, reducing fluid intake. (3) Dehydration reduces GFR, decreasing renal calcium excretion. (4) Higher serum calcium worsens symptoms further. Aggressive IV saline hydration breaks this cycle by restoring GFR and promoting calciuresis. This is always Step 1, regardless of severity.

Bisphosphonate Therapy: The Definitive Agent

Zoledronic acid (Zometa) 4 mg IV over 15 minutes is the most potent bisphosphonate available. It inhibits osteoclast-mediated bone resorption. However, its onset is 2 to 4 days (peak effect at 4 to 7 days). This is why calcitonin is used as a bridge (onset 4 to 6 hours) while waiting for bisphosphonate effect. Duration: 2 to 4 weeks per dose.

Alternative: Pamidronate 60 to 90 mg IV over 2 to 4 hours. Slightly less potent but available at lower cost in Indian hospitals.

Bisphosphonate Contraindication: In severe renal impairment (eGFR < 30 or Cr > 4.5 mg/dL), zoledronic acid carries significant nephrotoxicity risk. Use Denosumab 120 mg SC instead (RANKL inhibitor, not renally cleared). Onset: 2 to 4 days.
"Stones, Bones, Groans, and Psychiatric Overtones"

The classic mnemonic for hypercalcaemia symptoms: Stones (nephrolithiasis, nephrocalcinosis) · Bones (bone pain, osteitis fibrosa cystica, pathological fractures) · Groans (abdominal pain, constipation, nausea, pancreatitis, peptic ulcer disease) · Psychiatric overtones (anxiety, depression, confusion, psychosis, coma). Also: polyuria, polydipsia, shortened QT, band keratopathy.

Hypercalcaemia in TB and Granulomatous Disease

In Indian hospitals, tuberculosis is an important and often overlooked cause of hypercalcaemia. Activated macrophages in granulomata express 1-alpha hydroxylase, converting 25-OH vitamin D to active 1,25-dihydroxyvitamin D independently of PTH regulation. The result: unregulated calcium absorption. Check 1,25-dihydroxyvitamin D (will be high) and PTH (will be suppressed). Treatment: corticosteroids (Prednisolone 20 to 40 mg/day) rapidly reduce 1,25-D production and lower calcium. Also seen in sarcoidosis, Wegener granulomatosis, and fungal infections.

Abbreviations: AKI (Acute Kidney Injury) · ATPase (Adenosine Triphosphatase) · AV (Atrioventricular) · BD (Twice Daily) · Ca (Calcium) · CKD (Chronic Kidney Disease) · Cr (Creatinine) · ECG (Electrocardiogram) · eGFR (Estimated Glomerular Filtration Rate) · GFR (Glomerular Filtration Rate) · ICU (Intensive Care Unit) · IM (Intramuscular) · IV (Intravenous) · Na (Sodium) · NaCl (Sodium Chloride) · NF-kB (Nuclear Factor Kappa-B) · NS (Normal Saline) · PHPT (Primary Hyperparathyroidism) · PO (Per Os) · PTH (Parathyroid Hormone) · PTHrP (Parathyroid Hormone-related Peptide) · RANKL (Receptor Activator of NF-kB Ligand) · SC (Subcutaneous) · SPEP (Serum Protein Electrophoresis) · TB (Tuberculosis) · TdP (Torsades de Pointes) · UPEP (Urine Protein Electrophoresis) · 25-OH (25-Hydroxy) · 1,25-D (1,25-Dihydroxyvitamin D)
Algorithm References & Evidence Base
  1. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
  2. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722-1729.
  3. Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. J Intensive Care Med. 2015;30(5):235-252.
  4. Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022;328(16):1624-1636.
  5. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442-447.
How to Cite This Tool

AMA Style:
Umakanth S. Acute Hypercalcaemia Protocol. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Acute Hypercalcaemia Protocol [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Category Therapeutic & Management PathwaysProtocol
Specialties Internal Medicine, Oncology, Nephrology, Critical Care
Written and maintained by Dr Shashikiran Umakanth.
Last revised: 29 July 2026